Sign up for important Repatha® updates

Considering Repatha®? Want to get in touch with a Rep? Need practice information? Sign up today to stay connected.

First Name

Enter first name

Last Name

Enter last name


Enter email address

Zip Code

Enter zip code

I am a...

Select your title

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit


Thank you.



Repatha® helps the liver clear LDL cholesterol by limiting the actions of a protein called PCSK9—and less PCSK9 means less LDL-C in the blood.1

Statins reduce production of cholesterol

Via inhibition of HMG-CoA reductase, statins reduce the production of plasma cholesterol and lipoprotein.2

Repatha® enhances removal of LDL-cholesterol

By inhibiting PCSK9, Repatha® increases the number of LDL-C receptors on the surface of the liver, resulting in reduction of LDL-C from circulation.1

Repatha® mechanism of action1

What is PCSK9?

PCSK9 is a protein that promotes degradation of low density lipoprotein receptors (LDLRs). This results in fewer LDLRs on the liver cell surface, increasing plasma LDL-C levels.

Watch video


Why Repatha® inhibits PCSK9

By inhibiting the binding of PCSK9 to LDLR, Repatha® permits LDLRs to recycle back to the liver cell surface. This, in turn, increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels.

Watch video


How Repatha® lowers LDL-C levels

Repatha® lowers LDL-C levels by inhibiting PCSK9, increasing the number of LDLRs on the hepatocyte surface, thereby resulting in lower LDL-C plasma concentrations.

Watch video


References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Lipitor® (atorvastatin) prescribing information, Pfizer Inc.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

What is PCSK9?


Why Repatha® inhibits PCSK9


How Repatha® lowers LDL-C levels